Reata Pharmaceuticals, Inc. Securities Litigation

If you purchased a significant amount of shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA), you have certain options. Investors should contact us.

 

Lawsuit Overview

Defendant:Reata Pharmaceuticals, Inc.
Date Filed:October 15th, 2020
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:October 15th, 2019
Class End Date:August 7th, 2020

According to the Complaint, Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc., and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata is a clinical stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. Among Reata's drug candidates under development is omaveloxolone, which is in Phase 2 clinical development to treat Friedreich's ataxia ("FA"). Following the announcement of positive data from the MOXIe Part 2 study of omaveloxolone for FA in October 2019, the Company represented that it would seek submission for marketing approval of omaveloxolone for the treatment of FA in the U.S. with the FDA.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of FA in the U.S. without additional evidence; (ii) as a result, it was foreseeable that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Reata Pharmaceuticals, Inc.

 
First Identified Complaint

Toshif Patel, et al. v. Reata Pharmaceuticals, Inc., et al.

Date Filed:October 15th, 2020
Class Period Start:October 15th, 2019
Class Period End:August 7th, 2020
First Identified Complaint Filings
#Document TitleFiling Date